Physician profile
Susan Levit
NPI 1851316244
$1,266.29
in general payments reported to CMS, 2019-2025
22 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $86.81 · 2021: $210 · 2022: $179 · 2023: $272 · 2024: $227 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $280.50 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.89 | 2019-2024 | Trulance, Xifaxan |
| Amgen INC. | $130.59 | 2022-2025 | Evenity, Prolia |
| Lilly USA, LLC | $98.73 | 2019-2024 | Zepbound, Mounjaro |
| Shield Therapeutics INC | $68.72 | 2023-2024 | Accrufer |
| Ardelyx, INC. | $54.09 | 2024-2025 | Ibsrela |
| Amarin Pharma, INC. | $53.58 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $47.86 | 2019-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $44.44 | 2025 | Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $44.11 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $36.50 | 2023 | Wegovy, Saxenda, Ozempic |
| Pfizer INC. | $32.71 | 2019-2020 | |
| Boston Scientific Corporation | $26.67 | 2022 | |
| Astellas Pharma US INC | $23.50 | 2023 | Myrbetriq |
| Ironwood Pharmaceuticals, INC | $22.00 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.25 | 2019 | |
| Arbor Pharmaceuticals, INC. | $21.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.08 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $20.62 | 2023 | |
| Sanofi Pasteur INC. | $16.72 | 2022 | |
| Allergan, INC. | $16.67 | 2020 | |
| Vistapharm, INC. | $14.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Levit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.